Fast Forward LLC , a not-for-profit venture firm spun out of the National Multiple Sclerosis Society in the U.S., has partnered with EMD Serono Inc. to fill the funding gap between preclinical research and drug development...

Biotech advocates can be excused for their increasing frustration. Even as the industry's leaders continue to post profits, the BioCentury 100 lost another 2% last week and fell beneath the 1300 barrier (1295) for the...

With a 15 percent run up in the BioCentury 100 in the third quarter, it comes as no surprise that biotech companies are lining up to sell stock. While the window isn't wide open by...

The companies extended through February 2001, their May 1997 research collaboration to screen antibacterial and antifungal target proteins and discover inhibitors of these targets using Novalon's Biomolecular Recognition System (see BioCentury, May 12). In the...